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OBJECTIVE — To test the hypothesis that type 2 diabetes is associated with greater decline
in cognitive function in middle-aged individuals.
RESEARCH DESIGN AND METHODS — In the Dutch prospective Doetinchem Co-
hortStudy,cognitivefunctioningwasmeasuredtwicewithina5-yeartimeintervalin2,613men
and women. Participants were aged 43–70 years at baseline (1995–2002), and no one had a
history of stroke. Change in scores on global cognitive function as well as on speciﬁc cognitive
function domains (memory, speed of cognitive processes, and cognitive ﬂexibility) were com-
pared for respondents with and without type 2 diabetes (veriﬁed by the general practitioner or
random plasma glucose levels 11.1 mmol/l).
RESULTS — At the 5-year follow-up, the decline in global cognitive function in diabetic
patients was 2.6 times greater than that in individuals without diabetes. For individuals aged
60 years, patients with incident and prevalent diabetes showed a 2.5 and 3.6 times greater
decline, respectively, in cognitive ﬂexibility than individuals without diabetes. For most cogni-
tive domains, the magnitude of cognitive decline in patients with incident diabetes was inter-
mediate between that of individuals without diabetes and that of patients with diabetes at
baseline.
CONCLUSIONS — Middle-aged individuals with type 2 diabetes showed a greater decline
in cognitive function than middle-aged individuals without diabetes.
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T
ype 2 diabetes has been associated
with cognitive impairments (1) and
higher risks of developing vascular
dementia (2,3) and Alzheimer disease
(1,3). Cognitive dysfunction in type 2 di-
abetic patients may result from the inter-
action among metabolic abnormalities
intrinsic to diabetes (hyperglycemia and
hyperinsulinemia), diabetes-speciﬁc
complications (such as retinopathy, ne-
phropathy, and neuropathy), and other
diabetes-related disorders (such as isch-
emic heart disease, cerebrovascular dis-
ease, hypertension, low serum HDL
cholesterol, central obesity, and depres-
sion) (4).
Moststudiesoncognitivefunctioning
in relation to diabetes have been cross-
sectional or focused on elderly individu-
als(5,6).Wefoundonlyfourlongitudinal
studies in which changes in cognitive
functioning were evaluated in middle-
aged populations (7–10). Longitudinal
studies are needed to provide insight into
the development of cognitive impairment
and decline over time in relation to the
onset and duration of diabetes. None of
thefourstudiesevaluatedchangesincog-
nitive functioning in individuals with re-
cently diagnosed diabetes. Yet, to study
therelationbetweenonsetofdiabetesand
cognitive decline, it is essential to include
this group and measure cognitive func-
tion longitudinally, before and after the
onsetofdiabetes.Inthepresentstudy,we
tested the hypothesis that individuals
with prevalent diabetes at baseline and
those with incident diabetes during fol-
low-up show a greater decline in cogni-
tive functioning than individuals without
diabetes.
RESEARCH DESIGN AND
METHODS— The Doetinchem Co-
hort Study (DCS) (11) is an ongoing pro-
spective study, initially carried out in a
random general population sample of
7,769 men and women aged 20–59 years
(1987–1991).TheaimoftheDoetinchem
Cohort Study was to study the impact of
(changes in) lifestyle factors and biologi-
cal risk factors on various aspects of
health, such as the incidence of chronic
diseases, physical and cognitive function-
ing, and quality of life. The cohort is re-
examined every 5 years. At every
reexaminationlifestylefactorsandbiolog-
ical risk factors are assessed by question-
naires and a physical examination at the
research center. Three subsequent exam-
ination rounds were completed in the
years 1993–1997, 1998–2002, and
2003–2007. All participants gave written
informed consent. The study was ap-
proved by the external Medical Ethics
Committee of the Netherlands Organi-
zation of Applied Scientiﬁc Research
according to the guidelines of the Dec-
laration of Helsinki. Details on the DCS
have been extensively described else-
where (11).
From 1995 onward, cognitive testing
for DCS participants aged 45 years was
introduced. In the years 1995–1997, a
random sample of one-third of partici-
pants aged 45 years was enrolled in the
studyoncognitivefunctioning,andaran-
dom sample of two-thirds was enrolled in
an additional dietary study. Those partic-
ipating in the dietary study during 1995–
1997 had their baseline measurement of
cognitive functioning during 2000–
2002. Between 1995 and 2002, 3,350 re-
spondents aged 43–70 years, 96% of all
respondents invited, participated in cog-
nitive testing for the ﬁrst time. Five years
later, between 2000 and 2007, 2,690 of
them(80%)participatedincognitivetest-
ing again. At the ﬁrst cognitive testing,
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Centre for Prevention and Health Services Research, National Institute for Public Health and the
Environment, Bilthoven, the Netherlands.
Corresponding author: Astrid C.J. Nooyens, astrid.nooyens@rivm.nl.
Received 3 November 2009 and accepted 26 May 2010. Published ahead of print at http://care.
diabetesjournals.org on 2 June 2010. DOI: 10.2337/dc09-2038.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
ORIGINAL ARTICLE
1964 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.org55% of the population were 55 years
and 88% were 65 years of age. Partici-
pants who reported (at baseline or at fol-
low-up)havingexperiencedastroke(n
77) were excluded from the analyses, be-
cause stroke has direct effects on brain
functions and cognition. A total of 2,613
people (1,288 men and 1,325 women)
who participated in two cognitive mea-
surements were included in this study.
Cognitive tests
The neuropsychological test battery in-
cluded four tests, the 15-word Verbal
Learning Test (VLT), the Stroop Color
and Word Test (SCWT), a ﬂuency test,
and the Letter Digit Substitution Test
(LDST),tomeasureglobalcognitivefunc-
tion and speciﬁc cognitive domains,
namely memory, speed of cognitive pro-
cesses, and cognitive ﬂexibility (i.e.,
higher order information processing). In
the VLT, 15 monosyllabic words printed
on paper are displayed, one by one, in
three subsequent trials, with a free recall
procedureimmediatelyaftereachpresen-
tation (immediate recall). After a delay of
about 15 min, there is an additional free
recall trial (delayed recall). The VLT total
is calculated by summation of the words
recalled correctly on the three immediate
recalls. The VLT maximal represents the
highest score on one of the three immedi-
ate recalls. In the SCWT, three skills are
tested: 1) to read 40 written color names,
2) to name the color of 40 colored
patches, and 3) to name the color of the
ink in which 40 incongruously named
colorwordsareprinted(so,e.g.,theword
“blue” is printed in red). In the ﬂuency
test, the participant is asked to name as
manyanimalsaspossiblewithin1min.In
the LDST, nine letters are given a unique
digit code (1 to 9) in a key displayed on
thesamesheetofpaper.Theparticipantis
asked to ﬁll in the correct digits corre-
sponding to the letters, as fast as possible.
These tests are described in more detail
elsewhere(12).Thetestsaresensitiveto
age, also in the middle-age range. Cog-
nitive tests were performed by trained
investigators and took 20 min to
complete.
Distributions of scores on the SCWT
were normalized (distributions were uni-
modal and skewed to the right). For each
cognitive test, a z score was computed for
each participant at baseline and at follow-
up,basedonthemeansandSDsofthetest
scores at baseline. In this way we were
able to examine changes over time. Stan-
dardized scores on the SCWT were in-
verted, so that higher scores represent
better cognition. All (inverted) standard-
ized scores were then combined to form
scores for speciﬁc cognitive domains, i.e.,
scoresformemoryfunction,speedofcog-
nitive processes, and cognitive ﬂexibility,
and a summary score for global cognitive
function, as follows:
Memory function  (zVLTtotalzVLTmaximal
 zVLTdelayed recall)/3
Speed of cognitive processes
 (zln(SCWTcolor names)
 zln(SCWTcolor patches)  zLDST)/3
Cognitive ﬂexibility  zln(SCWTcolor link)
Global cognitive function
 (zln(SCWTcolor link)  zLDST
 zVLTtotal  zVLTdelayed recall 
zﬂuency)/5
Diabetes status
At baseline and at follow-up, participants
were asked whether they had diabetes by
means of a self-administered question-
naire. For all patients with self-reported
diabetes who had given written informed
consent for it, their general practitioner
was contacted for veriﬁcation via mailed
questionnaires. Almost all participants
gave consent (98.2%). For 90% of
patients with self-reported diabetes at
baseline and for 88% of those with
self-reported diabetes at follow-up,
information regarding their diabetes sta-
tus was obtained. Individuals with type 1
diabetes(n5)orwithanunknowntype
of diabetes (n  4) were excluded from
the analyses. Three individuals with self-
reported diabetes for whom the general
practitionerdidnotconﬁrmthediagnosis
andwomenwithgestationaldiabetesmel-
litus in the past but no diabetes at present
were classiﬁed as not having diabetes. In
addition, in the entire cohort a random
(nonfasting) venous blood sample was
taken to determine the plasma glucose
level with the hexokinase method (13).
For three individuals, plasma glucose
could not be determined. In conclusion,
diabetes was deﬁned on the basis of self-
report conﬁrmed by the general practitio-
ner, self-report alone (when no general
practitioner veriﬁcation was available), or
a random plasma glucose of 11.1
mmol/l (14).
Other measures
Several measures that are potentially as-
sociated with diabetes and/or cognitive
function were assessed. Each assessment
round included a physical examination at
the research center, involving height,
weight, waist circumference, and blood
pressure measurements and obtaining
nonfastingbloodsamples.BMIwasdeter-
mined as weight in kilograms divided by
thesquareofheightinmeters.Bloodpres-
sure was measured with the subject in the
sitting position using a random zero
sphygmomanometer. Total and HDL
cholesterol were measured using stan-
dardized enzymatic methods (11).
In every assessment, information on
demographiccharacteristics(e.g.,ageand
educational level), lifestyle factors (e.g.,
smoking, alcohol consumption, and
physical activity), and history of chronic
diseases (e.g., myocardial infarction) was
also collected using standardized ques-
tionnaires. Educational level was evalu-
ated as the highest level reached and
classiﬁed into ﬁve categories: 1) primary
school, 2) lower vocational education, 3)
intermediate secondary education, 4) in-
termediate vocational or higher second-
ary education, and 5) higher vocational
education or university. Smoking status
was deﬁned as being a nonsmoker (never
or former smoker) or smoker (of ciga-
rettes) and further according to the num-
berofpack-yearssmokedatbaseline.One
pack-yearcorrespondstosmoking20cig-
arettes/day for 1 year (or, e.g., smoking 1
cigarette/day for 20 years). Alcohol con-
sumption was classiﬁed into ﬁve catego-
ries: 1) abstainers, 2) 0–1 glasses/day, 3)
1–2 glasses/day, 4) 2–4 glasses/day, and
5) 4 glasses/day. Physical activity level
was assessed by the use of the validated
European Prospective Investigation into
Cancer and Nutrition (EPIC) question-
naire on physical activity (15) and classi-
ﬁed into four categories: inactive,
moderately inactive, moderately active,
and active (16).
Depressive symptoms were assessed
using the Dutch version (17) of the SF-36
(18). The scales “mental health” and “vi-
tality” evaluate symptoms of depression.
Scores on both scales range from 0 to 100
in which higher scores represent better
(mental) health.
Statistical analyses
Multivariate linear regression analyses
and ANCOVA were used to study the as-
sociation between diabetes status and
changesincognitivefunctionoverfollow-
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global cognitive function were analyzed
as continuous outcome measures, with
diabetes status as the main independent
measure. Two models were tested. First,
wetestedabasicmodel,adjustingforage,
sex, level of education, and baseline level
of cognitive function. Second, to ﬁnd out
whether associations between diabetes
andchangeincognitivefunctioncouldbe
explained by other diabetes-related fac-
tors, we tested the basic model with addi-
tional adjustment for factors of the
metabolic syndrome (waist circumfer-
ence,systolicbloodpressure,useofblood
pressure-lowering medication, and HDL
cholesterol level), physical activity, alco-
hol consumption, smoking, and history
of myocardial infarction. Because depres-
sion is quite common among people with
diabetes and depression negatively affects
cognitive function, we additionally ad-
justed this second model for depressive
symptoms (mental health and vitality).
Forallthesecovariates,baselinemeasures
were taken for inclusion in the analyses.
To test whether the association be-
tween diabetes and cognitive function
was different at both ends of the middle-
age range, additional analyses were per-
formed including an interaction term of
diabetes and age (60 vs. 60 years). All
analyses were performed using SAS (ver-
sion 9.2; SAS Institute, Cary, NC).
RESULTS— Nonparticipants and in-
dividuals lost to follow-up were slightly
older and less educated than individuals
who completed the follow-up assess-
ment.Individualslosttofollow-upscored
0.4 SDs lower at baseline on all cogni-
tive domains. In addition, the prevalence
of several cardiovascular risk factors was
higheramongthedropouts,andtheprev-
alence of type 2 diabetes (self-report or
plasma glucose level 11.1 mmol/l)
amongthemwasalsohigher(6.2vs.2.6%
in the follow-up group).
At follow-up, 139 individuals were
classiﬁed as having type 2 diabetes: 129
based on self-report (113 veriﬁed by the
general practitioner) and 10 based on
their elevated plasma glucose levels. Of
those 139, 61 (2.3% of the total popula-
tion; 31 men and 30 women) had preva-
lent diabetes at baseline, and 78 (3.0% of
the total population; 42 men and 36
women) developed type 2 diabetes dur-
ing follow-up (incident cases).
Patients with prevalent and incident
diabeteswereolderandlesseducatedand
had higher systolic blood pressure and
BMI at baseline than individuals without
diabetes. Furthermore, baseline cognitive
function in diabetic patients was worse
than that of individuals without diabetes
(Table 1).
Changes in cognitive function
We observed an interaction effect of dia-
beteswithage(60vs.60years)onthe
association between diabetes and change
in cognitive ﬂexibility. Therefore, results
for change in cognitive ﬂexibility will be
presented separately for individuals aged
60 years and those aged 60 years.
Prevalent diabetic patients showed
statistically signiﬁcantly greater declines
in memory function, cognitive ﬂexibility,
and global cognitive function than indi-
viduals without diabetes after adjustment
for age, sex, and educational level. Inci-
dentdiabeticpatientsshowedabouttwice
the decline observed in individuals with-
out diabetes, but this decline was statisti-
cally signiﬁcant for memory, speed, and
ﬂexibility (for individuals aged 60
years) only (Table 2).
In the fully adjusted model, cognitive
decline in memory, ﬂexibility, and global
cognitive function in prevalent diabetic
patients was about 3 times greater than
that in individuals without diabetes, al-
though this decline was statistically sig-
niﬁcantonlyforﬂexibility(forindividuals
aged 60 years) and global cognitive
function. Differences in cognitive decline
in memory and speed between incident
diabetic patients and individuals without
diabetes were no longer statistically sig-
niﬁcantinthefullyadjustedmodel(Table
2). Results of the fully adjusted model are
presented in Fig. 1. Associations between
diabetes status and changes in cognitive
function were not statistically signiﬁ-
cantly different for men compared with
women.
CONCLUSIONS — In the present
study, diabetic patients showed a greater






n 2,460 78 61
Age (years) 55.0  6.8 57.4  6.6 60.6  6.5
Sex (% women) 51.0 46.2 49.2
Level of education (% highly educated) 26.8 12.8 13.1
Cognitive function domain scores (z scores)
Memory function 0.01  0.94 0.00  0.89 0.53  0.87
Speed of cognitive processes 0.02  0.83 0.18  0.88 0.51  0.95
Cognitive ﬂexibility 0.02  0.99 0.33  1.00 0.30  1.41
Global cognitive function 0.02  0.72 0.19  0.66 0.45  0.75
Random glucose level (mmol/l) 5.3  0.9 6.9  1.6 11.4  3.9
Systolic blood pressure (mmHg) 130  17 143  19 142  18
Diastolic blood pressure (mmHg) 82  10 88  11 84  12
Use of blood pressure lowering medication
(%) 10.0 21.8 41.0
Total cholesterol (mmol/l) 5.84  1.00 6.09  1.19 5.70  1.02
HDL cholesterol (mmol/l), men 1.23  0.32 1.04  0.26 1.17  0.36
HDL cholesterol (mmol/l), women 1.55  0.38 1.20  0.33 1.23  0.23
History of myocardial infarction (%) 1.6 3.9 6.6
BMI (kg/m
2) 26.1  3.6 30.0  4.9 29.6  4.9
Waist circumference (cm), men 98.3  8.9 105.7  7.9 106.1  14.1
Waist circumference (cm), women 88.8  10.5 102.1  12.5 103.3  10.8
Physical activity (% inactive)* 24.6 24.4 37.7
Alcohol consumption (% 4 glasses/day) 4.8 9.0 1.6
Smoking (%) 22.2 23.4 14.8
Mental health* 77  15 78  13 77  18
Vitality* 68  17 66  17 65  18
DataaremeansSDunlessotherwiseindicated.Diabetesisdeﬁnedasself-reporteddiabetes(veriﬁedbythe
general practitioner) or having a random plasma glucose level 11.1 mmol/l. *Physical inactivity is deﬁned
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ﬂexibility and global cognitive function)
than individuals without diabetes. The
magnitude of decline in cognitive func-
tion in individuals who developed diabe-
tes during follow-up was between that of
individuals without diabetes and those
who had diabetes at baseline but was not
statistically signiﬁcantly different from ei-
ther group after adjustment for other car-
diovascular risk factors.
Strengths of the present study are its
prospective design, the relatively young
population, and the long follow-up pe-
riod with repeated assessment of cognitive
function using a sensitive cognitive test bat-
tery.Formostpatientswhoreporteddiabe-
tes, the diagnosis could be veriﬁed with
their general practitioner. Further, a large
number of covariates were assessed, which
enabled adjustment for a broad array of po-
tential confounders.
Limitations of the present study can
be found in the dropout of individuals
during follow-up. Although dropout of
this order of magnitude (20%) is inherent
to cohort studies, there are reasons to be-
lieve that in our study it was selective to
some extent. Overall, cognitive function
was better in the follow-up group and es-
pecially among individuals without dia-
betes. Based on associations in the
follow-up group, some of these observed
differences in baseline characteristics be-
tween the group of dropouts and the fol-
low-up group would weaken associations
between diabetes and change in cognitive
function, whereas other observed differ-
ences would make these associations
stronger. In addition, associations were
adjustedfortheseconfoundingcharacter-
istics. Therefore, the effect of dropouts on
the results will be only marginal.
Furthermore, we may have missed
some cases of diabetes because we mea-
sured random glucose levels rather than
fastingglucoselevels,andwedidthisonly
once.Todiagnosediabetes,twomeasure-
ments of glucose levels are recom-
mended. In addition, although most self-
reported cases of diabetes were veriﬁed
with the general practitioner, we cannot
exclude the possibility of some misclassi-
ﬁcations in the diabetic groups either. Be-
cause of these possible misclassiﬁcations,
the observed differences may be underes-
timations. In addition, no data on A1C
were available. Therefore, we could not
relate longer-term glucose levels to
changes in cognitive function.
The relation between diabetes and
cognitive decline in middle-aged individ-
uals was evaluated in three previous lon-
gitudinal studies (7–10). In the
Atherosclerosis Risk in Communities
(ARIC) Study, diabetic patients showed
greater declines over 6 and 14 years in
scores representing speed of cognitive
processes and verbal ﬂuency but not in
scores for memory (7,8). In the Interdis-
ciplinary Longitudinal Study of Aging
(ILSE) diabetic patients showed a greater
decline at 4 years of follow-up in intelli-
gence tasks but not in memory and speed
than individuals without diabetes (10).
Finally, in a study by van den Berg et al.
(9), no differences in cognitive decline on
several tests were observed between indi-
viduals with and without diabetes over a
4-year period. However, our study differs
from these studies as to the tests used to
determine cognitive domain functions.
Different tests might reveal different pat-
terns of decline. In addition, the age
ranges of the subjects were different
among the studies. Studying different
age-groups can result in different conclu-
sions, as reﬂected by the interaction be-
tweenageanddiabetesinourstudy.With
one exception (9), the overall conclusion
of the previous studies and ours is that
diabetes is associated with greater cogni-
tive decline in middle-aged individuals,
but that it remains uncertain which cog-
nitive domain is affected most.
Associations between incident diabe-
tes and cognitive decline have not been
studied before. The magnitude of cogni-
tive decline in incident diabetic patients
tendedtobesomewherebetweenthecog-
nitive decline in individuals without dia-
betes and that of patients with diabetes at
baseline,buttheobservedassociationwas
not signiﬁcant. Incident diabetic patients
may thus also beneﬁt from timely and ap-
propriate treatment at the level of cogni-
tive functions (19). Improved glycemic
control reduces the damaging effects of
hyperglycemia on neuronal and micro-
vascularstructures(5).Inthisrespect,itis
remarkable that random plasma glucose
levels of incident diabetic patients were
similar to those of prevalent diabetic pa-
tients (8.5 and 8.6 mmol/l, respectively),
which might be an indication that treat-
ment was insufﬁcient. However, random
plasma glucose is not the best indicator of
glycemic control.
Results of our study seem to indicate
that hyperglycemia affects different do-
mainsofcognitivefunctioningatdifferent
stagesofthediseaseprocess.Forinstance,
memory seems to be affected continu-
ously (lower score at baseline and a [bor-
derline signiﬁcantly] greater decline
during follow-up for diabetic patients),
whereas speed of cognitive processes
seems to be affected during the ﬁrst years
of hyperglycemia only (worse score at
baseline, but no greater decline over fol-
low-up for diabetic patients than for indi-
viduals without diabetes, whereas incident
diabetic patients show a greater decline in
speed of cognitive processes). These results
suggest that early treatment of hyperglyce-
mia could prevent some of the decline in
speed of cognitive processes, but probably
less so in the case of memory.
Table 2—Relative changes in cognitive function scores by diabetes status













Memory function 1.0 2.4§ 2.9§ 1.0 1.9 2.5‡
Speed of cognitive processes 1.0 1.9§ 1.2 1.0 1.5 1.0
Cognitive ﬂexibility
60 years 1.0 0.9 3.2 1.0 0.6 3.4
60 years 1.0 2.6§ 3.7 1.0 2.5‡ 3.6
Global cognitive function 1.0 1.9 2.8 1.0 1.6 2.6§
Relativedeclineincognitivedomainscoresisshownwithindividualswithnodiabetesasthereferencegroup:
in the reference group of “healthy” individuals, we set the cognitive decline to 1.0. The numbers in the
columns of patients with diabetes reﬂect how many times stronger the cognitive decline was among diabetic





adjusted for age, sex, level of education, waist circumference, HDL cholesterol level, systolic blood pressure,
use of blood pressure-lowering medication, history of myocardial infarction, depressive symptoms (vitality
and mental health), physical activity, alcohol consumption, smoking, and baseline cognitive score. ‡Differ-
ent from no diabetes group at P  0.10; §P  0.05; P  0.01.
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sizedbetweentype2diabetesandcognitive
decline. For example, hyperglycemia
causes oxidative stress and glycation of
important functional and structural pro-
teins (20), which can have a direct detri-
mental effect on brain cells and the
microcirculation in the brain (21). In ad-
dition, higher fasting plasma glucose has
been associated with functional changes
in regional cerebral perfusion (22). In ad-
dition, type 2 diabetes is associated with
increased central arterial stiffness (23),
which has been shown to be a strong pre-
dictor of loss in cognitive function in
older individuals (24). Improvement in
glycemic control may improve cognitive
functioning in adults with type 2 diabetes
(19) and reduce the risk for (cardiovascu-
lar) complications.
Because we observed that cognitive
declinewasgreaterinprevalentdiabetic
patients than in incident diabetic pa-
tients and individuals without diabetes,
duration of exposure to hyperglycemia
could be the main factor that induces
andmaintainscognitivedecline.Tofur-
ther explore this hypothesis, we per-
formed ad hoc analyses on a subset of
our data, relating diabetes duration to
cognitive decline. A veriﬁed date of di-
agnosisofdiabeteswasavailablefor109
(57 incident and 52 prevalent) diabetic
patients at follow-up. On average, dia-
betes in these patients had been diag-
nosed 6.5  6.8 (mean  SD) years
before the follow-up assessment. We
did not observe an association between
duration of diabetes and change in cog-
nitive functioning within this subgroup
of diabetic patients. Thus, this result
did not conﬁrm our hypothesis.
Type 2 diabetes is often associated
with other conditions that may inﬂuence
cognitive function, such as hypertension,
hypercholesterolemia, and central obe-
sity. Therefore, we adjusted for these car-
diovascular risk factors. However, trends
observedinthefullyadjustedmodelwere
similar to those in the basic model, indi-
cating that comorbidities of diabetes only
partly explain the associations between
diabetes and cognitive decline.
In summary, middle-aged diabetic
patients have greater cognitive decline
than individuals without diabetes. There-
fore, cognitive function should be as-
sessed and monitored in middle-aged
individuals with type 2 diabetes.
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